The Venture Codex

Participated · Series A · Sep 2025

AiM Medical Robotics is building a compact, portable robotic platform that operates directly inside an MRI scanner, giving neurosurgeons continuous, real-time imaging while they position instruments. The technology targets deep-brain stimulation lead placement for Parkinson’s disease and other movement disorders, and can be adapted for cranial biopsies, tumor and epilepsy ablations, and targeted intracranial drug delivery. By eliminating the need to shuttle patients between the operating room and imaging suite, the system seeks to make procedures faster, safer, and more precise, lowering both risk and cost. The company plans to layer artificial intelligence onto the platform so it can learn from surgical data, optimize workflows, and provide predictive guidance. AiM estimates its initial DBS market opportunity at $7.9 billion. Including the new capital, the company has secured over $11.3 million in equity funding, supplemented by significant federal grants. The fresh funds will support first-in-human trials, regulatory progress, and expansion of strategic partnerships.

Participated · Equity · Jul 2024

House of Biryani operates as a digitally native, cloud-kitchen brand that focuses on biryani and complementary Indian dishes distributed via platforms such as Swiggy and Zomato. The company positions itself within India’s fast-growing D2C food ecosystem, emphasising an omnichannel strategy that blends online ordering with branded menu collaborations. Recent initiatives include the launch of the “AP Menu,” a special line curated with actor-investor Amol Parashar to drive customer engagement. Celebrity involvement is central to the brand narrative; former Indian cricket captain M S Dhoni and now Amol Parashar lend both capital and public credibility. Management highlights that its investors provide strategic input in branding, influencer marketing, and market expansion, not just funding. Although specific revenue, user counts, or profitability metrics were not disclosed, the company underscores scalable growth through its cloud-kitchen model and quick-commerce partnerships. Overall, House of Biryani aims to leverage celebrity equity and digital distribution to accelerate nationwide expansion and deepen consumer trust.

Participated · Seed · Aug 2022

Remedium Bio is advancing a proprietary Prometheus™ platform designed to enable controlled, long-lasting expression of therapeutic proteins by harnessing adipocytes as a durable site for production. The platform aims to provide multi-year benefit with adjustable dosing following minimally invasive subcutaneous administration and to replace many subcutaneously administered protein therapies with single-injection, adjustable gene therapies. Its pipeline includes programs targeting endocrinology, immunology, neurology, and musculoskeletal diseases. The company recently completed an initial closing of a $10 million Series A led by LifeSpan Vision Ventures, with participation from Eli Lilly and Company and HKX Capital. Remedium is using the financing to advance lead programs, expand the platform, and prepare for first-in-human clinical studies. The announcement was issued from Norwalk, Connecticut.